Literature DB >> 16107958

A soluble receptor decoy protects rats against anthrax lethal toxin challenge.

Heather M Scobie1, Diane Thomas, John M Marlett, Giuseppe Destito, Darran J Wigelsworth, R John Collier, John A T Young, Marianne Manchester.   

Abstract

Successful postexposure treatment for inhalation anthrax is thought to include neutralization of anthrax toxin. The soluble anthrax toxin receptor/tumor endothelial marker 8 and capillary morphogenesis protein 2 (sATR/TEM8 and sCMG2, respectively) receptor decoys bind to anthrax toxin protective antigen (PA) and compete with cellular receptors for binding. Here, we show that, in a tissue-culture model of intoxication, sCMG2 is a 11.4-fold more potent antitoxin than sATR/TEM8 and that this increased activity corresponds to an approximately 1000-fold higher PA-binding affinity. Stoichiometric concentrations of sCMG2 protect rats against lethal toxin challenge, making sCMG2 one of the most effective anthrax antitoxins described to date.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16107958     DOI： 10.1086/432731

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  43 in total

1.  Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells.

Authors:  Kuang-Hua Chen; Shihui Liu; Laurie A Bankston; Robert C Liddington; Stephen H Leppla
Journal:  J Biol Chem       Date:  2007-01-24       Impact factor: 5.157

2.  Imaging tumor endothelial marker 8 using an 18F-labeled peptide.

Authors:  Qimeng Quan; Min Yang; Haokao Gao; Lei Zhu; Xin Lin; Ning Guo; Guixiang Zhang; Henry S Eden; Gang Niu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-04       Impact factor: 9.236

Review 3.  Anti-virulence strategies to combat bacteria-mediated disease.

Authors:  David A Rasko; Vanessa Sperandio
Journal:  Nat Rev Drug Discov       Date:  2010-01-18       Impact factor: 84.694

4.  Identification of a claudin-4 residue important for mediating the host cell binding and action of Clostridium perfringens enterotoxin.

Authors:  Susan L Robertson; James G Smedley; Bruce A McClane
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

5.  Identification of small molecules that inhibit the interaction of TEM8 with anthrax protective antigen using a FRET assay.

Authors:  Lorna M Cryan; Kaiane A Habeshian; Thomas P Caldwell; Meredith T Morris; P Christine Ackroyd; Kenneth A Christensen; Michael S Rogers
Journal:  J Biomol Screen       Date:  2013-03-11

6.  Efficient neutralization of antibody-resistant forms of anthrax toxin by a soluble receptor decoy inhibitor.

Authors:  Shilpi Sharma; Diane Thomas; John Marlett; Marianne Manchester; John A T Young
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

7.  The structure of tumor endothelial marker 8 (TEM8) extracellular domain and implications for its receptor function for recognizing anthrax toxin.

Authors:  Sheng Fu; Xiaohang Tong; Chenguang Cai; Ying Zhao; Yang Wu; Yuanyuan Li; Junjie Xu; Xuejun C Zhang; Long Xu; Wei Chen; Zihe Rao
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

8.  Transcriptional stimulation of anthrax toxin receptors by anthrax edema toxin and Bacillus anthracis Sterne spore.

Authors:  Qingfu Xu; Eric D Hesek; Mingtao Zeng
Journal:  Microb Pathog       Date:  2007-03-15       Impact factor: 3.738

9.  Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy.

Authors:  Sunil K Joshi; Gillian A Lang; Jason L Larabee; T Scott Devera; Lindsay M Aye; Hemangi B Shah; Jimmy D Ballard; Mark L Lang
Journal:  PLoS Pathog       Date:  2009-09-25       Impact factor: 6.823

10.  Anthrax toxin receptor 2 is expressed in murine and tumor vasculature and functions in endothelial proliferation and morphogenesis.

Authors:  C V Reeves; J Dufraine; J A T Young; J Kitajewski
Journal:  Oncogene       Date:  2009-11-09       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.